

OIE Reference Laboratory Reports Activities

Activities in 2019

This report has been submitted : 2020-01-29 16:58:38

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Equine rhinopneumonitis
Address of laboratory:	Johnstown Naas Co. Kildare IRELAND
Tel.:	+353-45 86.62.66
Fax:	+353-45 86. 62.73
E-mail address:	acullinane@irishequinecentre.ie
Website:	www.irishequinecentre.ie
Name (including Title) of Head of Laboratory (Responsible Official):	Sarah McNicholas BBS MSc Chief Executive Officer
Name (including Title and Position) of OIE Reference Expert:	Professor Ann Cullinane Head of Virology
Which of the following defines your laboratory? Check all that apply:	Other: Registered Charity

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
CFT	Yes	531	448
SNT	Yes	50	411
Direct diagnostic tests			
Real Time PCR	Yes	2116	169

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Antiserum from experimentally infected pony	SNT	Produced	0	10ml	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
FRANCE	June	19	0
FRANCE	April	0	18

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
SWEDEN	Control of neurological outbreak	Remote
FRANCE	Implications for loss of performance	Remote

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Molecular surveillance of EHV-1 strains circulating in France since 2009	2017-2019	Phylogenetic analysis of viruses from outbreaks of abortion, respiratory disease and neurological disease outbreaks	LABÉO, 14280 Saint-Contest, France;	FRANCE
Concurrent Vaccination of Young Sporthorses	2018- 2020	Development of Science based vaccination regimes	Hanover University	GERMANY

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Epidemiological investigation of outbreaks. Virus isolation, real time PCR, serology, molecular characterisation of viruses and phylogenetic analysis

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
As above nationally and internationally. See publications listed below.

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 2

Molecular Characterisation of Equine Herpesvirus 1 Isolates from Cases of Abortion, Respiratory and Neurological Disease in Ireland between 1990 and 2017. Garvey M, Lyons R, Hector RD, Walsh C, Arkins S, Cullinane A. Pathogens. 2019 Jan 15;8(1). pii: E7. doi: 10.3390/pathogens8010007.

Molecular Surveillance of EHV-1 Strains Circulating in France During and After the Major 2009 Outbreak in Normandy Involving Respiratory Infection, Neurological Disorder, and Abortion. Sutton G, Garvey M, Cullinane A, Jourdan M, Fortier C, Moreau P, Foursin M, Gryspeerdt A, Maisonnier V, Marcillaud-Pitel C, Legrand L, Paillot R, Pronost S. Viruses. 2019 Oct 4;11(10). pii: E916. doi:

b) International conferences: 2

SIVE - National Federation of Equine Veterinarians in Italy - Presentation entitled "Clinical Aspects of Equine Viral Disease"

European Equine Infectious Diseases Meeting, Caen, Normandy - Presentation entitled Molecular characterisation of equid herpesviruses 1 and 8 in clinical samples

c) National conferences: 2

Veterinary Ireland Annual Conference for Equine Group - 2019 Update on Equine Viral Disease

Irish Thoroughbred Breeders Winter Seminar Series - Biosecurity for the 2020 Breeding Season- Minimise the Threat of Viral Disease

d) Other:

(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member

Countries?

Yes

- a) Technical visits: 2
- b) Seminars: 0
- c) Hands-on training courses: 2
- d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
a	Japan	2
a	France	3
c	Germany	1
c	France	1

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025	-The-Irish-Equine-Foundation-Ltd-151T-Cert.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Detection of EHV1 by real time PCR	INAB
Quantification of EHV1 by real time PCR	INAB

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

Yes

National/ International	Title of event	Co-organiser	Date (mm/yy)	Location	No. Participants
International	FEEVA Disease Surveillance Network IV Summit	Don Collins and Miguel Llorca	September 2019	Kildare	23
International	Expert Surveillance Panel for Equine Influenza	Gounalan Pavade	April 2019	OIE Headquarters	13

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
13th OIE Seminar at the International Symposium of the World Association of Veterinary Laboratory Diagnosticians (ISWALVD)	June 2019	Chang Mai , Thailand	Speaker	Quality systems: protection against litigation

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: ¹	Role of your Reference Laboratory (organiser/participant)	No. participants	Participating OIE Ref. Labs/organising OIE Ref. Lab.
Quality Control and Maintenance of INAB Accreditation	organiser and participant	2	Animal Health Trust and Irish Equine Centre

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
Quality Control	2	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Member of Biological Standards Commission	OIE Headquarters	International Standards for Diagnostic Tests and Vaccines
Representative of Biological Standards Commission at Ad hoc Kick-off Meeting of the OIE Virtual Biobank project	OIE Headquarters	Compilation of a Global Veterinary Biobank which will facilitate the distribution of reference standards and diagnostic materials internationally.
Revision of Manual in response to comments from BSC	Remote	Biotechnology Advances in Diagnosis of Infectious Disease
Compilation of ESP recommendations for publication in OIE Bulletin	Remote	Vaccine Composition
Manuscript review for publication	Remote	Equine Influenza

25. Additional comments regarding your report: